Picture of Spectral Medical logo

EDT Spectral Medical Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+1.29%
3m-8.76%
6m+44.53%
1yr+16.3%
Volume Change (%)
10d/3m+33.09%
Price vs... (%)
52w High-7.87%
50d MA-1.49%
200d MA+19.49%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-1088.63%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Spectral Medical EPS forecast chart

Profile Summary

Spectral Medical Inc. is a Canada-based late-stage theranostic company focused on advancing therapeutic solutions for sepsis and septic shock. The Company develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The Company also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. It provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.

Directors

Last Annual
December 31st, 2024
Last Interim
March 31st, 2025
Incorporated
April 1st, 2005
Public Since
July 16th, 1992
No. of Employees
29
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
285,819,699

EDT Share Price Performance

Upcoming Events for EDT

Q2 2025 Spectral Medical Inc Earnings Release

Q3 2025 Spectral Medical Inc Earnings Release

Similar to EDT

Picture of Aptose Biosciences logo

Aptose Biosciences

ca flag iconToronto Stock Exchange

Picture of Aurora Cannabis logo

Aurora Cannabis

ca flag iconToronto Stock Exchange

Picture of Auxly Cannabis logo

Auxly Cannabis

ca flag iconToronto Stock Exchange

Picture of Bausch Health Companies logo

Bausch Health Companies

ca flag iconToronto Stock Exchange

Picture of Canopy Growth logo

Canopy Growth

ca flag iconToronto Stock Exchange

FAQ